{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T07:03:34Z","timestamp":1774940614607,"version":"3.50.1"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Aging Neurosci."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder with limited treatments. Stromal vascular fraction (SVF), a cell population derived from autologous adipose tissue, exhibits multimodal immunomodulatory and neuroprotective properties, positioning it as a promising therapeutic candidate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This trial aimed to assess autologous stromal vascular fraction (SVF) safety and efficacy in patients with ALS. 26 patients received combined intravenous (0.5 \u00d7 10\n                      <jats:italic>6<\/jats:italic>\n                      cells\/kg) and intrathecal (20 \u00d7 10\n                      <jats:sup>6<\/jats:sup>\n                      cells) autologous SVF (An exploratory second dose of SVF was administered intrathecally to three patients 45 days later). The trial is registered with the Chinese Clinical Trial Registry (ChiCTR2400091754).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      SVF administration was well-tolerated. Five mild adverse events (adverse events, AEs) (subcutaneous bleeding, headache, and low-grade fever) occurred, with no serious AEs reported. Although ALSFRS-R scores showed non-significant improvement post-treatment, 15\/26 participants (57.7%) self-reported symptomatic improvement after treatment. Critically, cerebrospinal fluid biomarker analysis revealed significant reductions in neurofilament light chain (NfL; \u0394530.29 pg\/mL,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.039) and glial fibrillary acidic protein (GFAP; \u0394622.23 pg\/mL,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.038), indicating attenuation of neuroaxonal degeneration and astroglial activation. While ALSFRS-R scores showed no significant change (\u0394-0.53,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.384), prognostic modeling identified female sex (OR = 0.011,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.008) and shorter disease duration (OR = 1.35\/month, P = 0.005) as predictors of response. Three patients who underwent the second treatment were well tolerated without any adverse events.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings indicate that Autologous SVF therapy might possess an acceptable safety profile for patients with ALS. The significant reduction in CSF NfL and GFAP levels provides objective evidence of their potential neuroprotective effects that modulates ALS-relevant neuroinflammation pathways. Female participants and those with shorter disease duration may derive greater benefits.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnagi.2026.1784115","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T05:32:34Z","timestamp":1774935154000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Autologous SVF therapy modulates neuroinflammation in ALS: phase I trial demonstrating safety and CSF biomarker dynamics"],"prefix":"10.3389","volume":"18","author":[{"given":"Ruixia","family":"Li","sequence":"first","affiliation":[{"name":"Department of Neurology, Suzhou Hospital, Affiliated Hospital of Medical School, Nanjing University","place":["Suzhou, China"]},{"name":"Suzhou Research Center of Medical School, Suzhou Hospital, Affiliated Hospital of Medical School, Nanjing University","place":["Suzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Suzhou Hospital, Affiliated Hospital of Medical School, Nanjing University","place":["Suzhou, China"]},{"name":"Suzhou Research Center of Medical School, Suzhou Hospital, Affiliated Hospital of Medical School, Nanjing University","place":["Suzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendi","family":"Bu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Gulou School of Clinical Medicine, Nanjing Medical University, Nanjing","place":["Jiangsu, China"]},{"name":"Department of Neurology, Suqian Zhongwu Hospital","place":["Suqian, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Suzhou Hospital, Affiliated Hospital of Medical School, Nanjing University","place":["Suzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurology, Suzhou Hospital, Affiliated Hospital of Medical School, Nanjing University","place":["Suzhou, China"]},{"name":"Suzhou Research Center of Medical School, Suzhou Hospital, Affiliated Hospital of Medical School, Nanjing University","place":["Suzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurology, Suzhou Hospital, Affiliated Hospital of Medical School, Nanjing University","place":["Suzhou, China"]},{"name":"Suzhou Research Center of Medical School, Suzhou Hospital, Affiliated Hospital of Medical School, Nanjing University","place":["Suzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiahui","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Suzhou Hospital, Affiliated Hospital of Medical School, Nanjing University","place":["Suzhou, China"]},{"name":"Suzhou Research Center of Medical School, Suzhou Hospital, Affiliated Hospital of Medical School, Nanjing University","place":["Suzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingwei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurology, Suzhou Hospital, Affiliated Hospital of Medical School, Nanjing University","place":["Suzhou, China"]},{"name":"Suzhou Research Center of Medical School, Suzhou Hospital, Affiliated Hospital of Medical School, Nanjing University","place":["Suzhou, China"]},{"name":"Department of Neurology, Gulou School of Clinical Medicine, Nanjing Medical University, Nanjing","place":["Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zenglin","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Neurology, Suzhou Hospital, Affiliated Hospital of Medical School, Nanjing University","place":["Suzhou, China"]},{"name":"Suzhou Research Center of Medical School, Suzhou Hospital, Affiliated Hospital of Medical School, Nanjing University","place":["Suzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1002\/hipo.22405","article-title":"Human neural stem cells improve cognition and promote synaptic growth in two complementary transgenic models of Alzheimer\u2019s disease and neuronal loss.","volume":"25","author":"Ager","year":"2015","journal-title":"Hippocampus"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.2741\/4285","article-title":"An update on drug treatment options of Alzheimer\u2019s disease.","volume":"19","author":"Allgaier","year":"2014","journal-title":"Front. Biosci"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1016\/j.jcyt.2016.08.005","article-title":"Intraspinal stem cell transplantation for amyotrophic lateral sclerosis: ready for efficacy clinical trials?","volume":"18","author":"Atassi","year":"2016","journal-title":"Cytotherapy"},{"key":"B4","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1007\/s12015-020-10016-7","article-title":"Umbilical cord mesenchymal stem cells in amyotrophic lateral sclerosis: an original study.","volume":"16","author":"Barczewska","year":"2020","journal-title":"Stem Cell Rev. Rep"},{"key":"B5","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1159\/000493018","article-title":"Advances and current challenges associated with the use of human induced pluripotent stem cells in modeling neurodegenerative disease.","volume":"205","author":"Berry","year":"2018","journal-title":"Cells Tissues Organs"},{"key":"B6","doi-asserted-by":"publisher","first-page":"13594","DOI":"10.1073\/pnas.0901402106","article-title":"Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease.","volume":"106","author":"Blurton-Jones","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"B7","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13287-017-0598-y","article-title":"Adipose tissue-derived stromal vascular fraction in regenerative medicine: a brief review on biology and translation.","volume":"8","author":"Bora","year":"2017","journal-title":"Stem Cell Res. Ther"},{"key":"B8","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.jcyt.2013.02.006","article-title":"Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal\/stem cells: a joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT).","volume":"15","author":"Bourin","year":"2013","journal-title":"Cytotherapy"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1002\/stem.2689","article-title":"Immunomodulatory effects of adipose stromal vascular fraction cells promote alternative activation macrophages to repair tissue damage.","volume":"35","author":"Bowles","year":"2017","journal-title":"Stem Cells"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.3390\/ijms21093103","article-title":"Neural stem cell transplantation for neurodegenerative diseases.","volume":"21","author":"De Gioia","year":"2020","journal-title":"Int. J. Mol. Sci"},{"key":"B11","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/ana.27133","article-title":"Elevated cerebrospinal fluid ubiquitin carboxyl-terminal hydrolase isozyme L1 in asymptomatic C9orf72 hexanucleotide repeat expansion carriers.","volume":"97","author":"Dellar","year":"2025","journal-title":"Ann. Neurol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1002\/cbin.10099","article-title":"Stromal vascular fraction (SVF) cells enhance long-term survival of autologous fat grafting through the facilitation of M2 macrophages.","volume":"37","author":"Dong","year":"2013","journal-title":"Cell Biol. Int"},{"key":"B13","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1136\/jnnp-2021-327503","article-title":"Cerebrospinal fluid biomarkers of disease activity and progression in amyotrophic lateral sclerosis.","volume":"93","author":"Dreger","year":"2022","journal-title":"J. Neurol Neurosurg. Psychiatry"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1002\/sctm.16-0337","article-title":"Concise review: fat and furious: harnessing the full potential of adipose-derived stromal vascular fraction.","volume":"6","author":"Dykstra","year":"2017","journal-title":"Stem Cells Transl. Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41582-024-01049-4","article-title":"Targeting common disease pathomechanisms to treat amyotrophic lateral sclerosis.","volume":"21","author":"Faller","year":"2025","journal-title":"Nat. Rev. Neurol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1093\/stcltm\/szad041","article-title":"Neural cells for neurodegenerative diseases in clinical trials.","volume":"12","author":"Fan","year":"2023","journal-title":"Stem Cells Transl. Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1002\/med.21322","article-title":"The gap between the physiological and therapeutic roles of mesenchymal stem cells.","volume":"34","author":"Galderisi","year":"2014","journal-title":"Med. Res. Rev"},{"key":"B18","doi-asserted-by":"publisher","first-page":"eadj9332","DOI":"10.1126\/scitranslmed.adj9332","article-title":"Immunological drivers of amyotrophic lateral sclerosis.","volume":"15","author":"Gendron","year":"2023","journal-title":"Sci. Transl. Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12967-023-03903-3","article-title":"Safety and efficacy of first-in-man intrathecal injection of human astrocytes (AstroRx\u00a7) in ALS patients: phase I\/IIa clinical trial results.","volume":"21","author":"Gotkine","year":"2023","journal-title":"J. Transl. Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/icb.2012.67","article-title":"Anti-donor immune responses elicited by allogeneic mesenchymal stem cells: What have we learned so far?","volume":"91","author":"Griffin","year":"2013","journal-title":"Immunol. Cell Biol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"17071","DOI":"10.1038\/nrdp.2017.71","article-title":"Amyotrophic lateral sclerosis.","volume":"3","author":"Hardiman","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"B22","doi-asserted-by":"publisher","first-page":"115525","DOI":"10.1016\/j.addr.2025.115525","article-title":"Clinical perspective on pluripotent stem cells derived cell therapies for the treatment of neurodegenerative diseases.","volume":"218","author":"Izrael","year":"2025","journal-title":"Adv. Drug Deliv. Rev"},{"key":"B23","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.bbi.2023.01.013","article-title":"Profiling TREM2 expression in amyotrophic lateral sclerosis.","volume":"109","author":"Jeric\u00f3","year":"2023","journal-title":"Brain Behav. Immun"},{"key":"B24","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/asj\/sjv164","article-title":"Prospective 1-year follow-up study of breast augmentation by cell-assisted lipotransfer.","volume":"36","author":"Jung","year":"2016","journal-title":"Aesthet Surg. J"},{"key":"B25","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41582-020-00434-z","article-title":"Improving clinical trial outcomes in amyotrophic lateral sclerosis.","volume":"17","author":"Kiernan","year":"2021","journal-title":"Nat. Rev. Neurol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1161\/ATVBAHA.110.218206","article-title":"Stromal vascular fraction from adipose tissue forms profound vascular network through the dynamic reassembly of blood endothelial cells.","volume":"31","author":"Koh","year":"2011","journal-title":"Arterioscler Thromb. Vasc. Biol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1046\/j.1365-3083.2003.01176.x","article-title":"Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex.","volume":"57","author":"Le Blanc","year":"2003","journal-title":"Scand. J. Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/nm1746","article-title":"Lewy bodies in grafted neurons in subjects with Parkinson\u2019s disease suggest host-to-graft disease propagation.","volume":"14","author":"Li","year":"2008","journal-title":"Nat. Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/j.1748-720X.2010.00486.x","article-title":"Resolving ethical issues in stem cell clinical trials: the example of Parkinson disease.","volume":"38","author":"Lo","year":"2010","journal-title":"J. Law Med. Ethics"},{"key":"B30","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/scrt488","article-title":"Changes in immunological profile of allogeneic mesenchymal stem cells after differentiation: Should we be concerned?","volume":"5","author":"Lohan","year":"2014","journal-title":"Stem Cell Res. Ther"},{"key":"B31","doi-asserted-by":"publisher","first-page":"S113","DOI":"10.3727\/096368913X672181","article-title":"Intracerebral transplantation of adipose-derived mesenchymal stem cells alternatively activates microglia and ameliorates neuropathological deficits in Alzheimer\u2019s disease mice.","volume":"22","author":"Ma","year":"2013","journal-title":"Cell Transplant"},{"key":"B32","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1080\/13543784.2017.1323868","article-title":"Why do trials for Alzheimer\u2019s disease drugs keep failing? A discontinued drug perspective for 2010-2015.","volume":"26","author":"Mehta","year":"2017","journal-title":"Expert Opin. Investig. Drugs"},{"key":"B33","doi-asserted-by":"publisher","first-page":"369","DOI":"10.5966\/sctm.2014-0252","article-title":"Systemically delivered adipose stromal vascular fraction cells disseminate to peripheral artery walls and reduce vasomotor tone through a CD11b+ cell-dependent mechanism.","volume":"4","author":"Morris","year":"2015","journal-title":"Stem Cells Transl. Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3389\/fnagi.2017.00068","article-title":"ALS clinical trials review: 20 years of failure. Are we any closer to registering a new treatment?","volume":"9","author":"Petrov","year":"2017","journal-title":"Front. Aging Neurosci."},{"key":"B35","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1089\/ten.TEB.2017.0061","article-title":"The adipose stromal vascular fraction as a complex cellular source for tissue engineering applications.","volume":"24","author":"Ramakrishnan","year":"2018","journal-title":"Tissue Eng. Part B Rev"},{"key":"B36","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1479-5876-7-29","article-title":"Non-expanded adipose stromal vascular fraction cell therapy for multiple sclerosis.","volume":"7","author":"Riordan","year":"2009","journal-title":"J. Transl. Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1126\/science.aar7112","article-title":"Personalized vaccines for cancer immunotherapy.","volume":"359","author":"Sahin","year":"2018","journal-title":"Science"},{"key":"B38","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1161\/STROKEAHA.109.563015","article-title":"The postischemic environment differentially impacts teratoma or tumor formation after transplantation of human embryonic stem cell-derived neural progenitors.","volume":"41","author":"Seminatore","year":"2010","journal-title":"Stroke"},{"key":"B39","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/nature22815","article-title":"T cells from patients with Parkinson\u2019s disease recognize \u03b1-synuclein peptides.","volume":"546","author":"Sulzer","year":"2017","journal-title":"Nature"},{"key":"B40","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","article-title":"Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors.","volume":"126","author":"Takahashi","year":"2006","journal-title":"Cell"},{"key":"B41","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1097\/01.TP.0000045055.63901.A9","article-title":"Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation.","volume":"75","author":"Tse","year":"2003","journal-title":"Transplantation"},{"key":"B42","doi-asserted-by":"publisher","first-page":"3760","DOI":"10.1093\/brain\/awad120","article-title":"Genetic variability in sporadic amyotrophic lateral sclerosis.","volume":"146","author":"Van Daele","year":"2023","journal-title":"Brain"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1136\/jnnp-2025-336208","article-title":"CSF levels of the somatodendritic protein MAP2 are increased in ALS and predict shorter survival.","volume":"96","author":"Verde","year":"2025","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B44","doi-asserted-by":"publisher","first-page":"5856","DOI":"10.1073\/pnas.0801677105","article-title":"Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson\u2019s disease.","volume":"105","author":"Wernig","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"B45","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1136\/jnnp-2021-328710","article-title":"Development of a sensitive trial-ready poly(GP) CSF biomarker assay for C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis.","volume":"93","author":"Wilson","year":"2022","journal-title":"J. Neurol Neurosurg. Psychiatry"}],"container-title":["Frontiers in Aging Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2026.1784115\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T05:32:35Z","timestamp":1774935155000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2026.1784115\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":45,"alternative-id":["10.3389\/fnagi.2026.1784115"],"URL":"https:\/\/doi.org\/10.3389\/fnagi.2026.1784115","relation":{},"ISSN":["1663-4365"],"issn-type":[{"value":"1663-4365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"article-number":"1784115"}}